Latest News by Industry
DUBLIN--(BUSINESS WIRE)--Nov 7, 2022--
The "Crohn's Disease Therapeutics Market Forecast - Epidemiology & Pipeline Analysis" report has been added to ResearchAndMarkets.com's offering.
Crohn's disease is an inflammatory bowel disease (IBD) that causes digestive tract inflammation, leading to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The inflammatory bowel disease treatment market can be segmented into two types, i.e., Crohn's Disease and Ulcerative Colitis. Among these, Crohn's Disease dominates the global market.
According to estimates, the prevalence of Crohn's Disease was high in the United States, followed by the UK and China, in 2020. The increasing prevalence of Crohn's Disease is driving the growth of the Crohn's Disease drugs market. According to estimates, one million people were affected with Crohn's Disease in the US in 2019.
Market Drivers:
Adoption of Biologics: Biological therapies such as anti-tumor necrosis factor (TNF), anti-interleukin & integrin antibodies are widely used for various inflammatory diseases such as Crohn's disease (CD). These are considered generally satisfactory in treating patients who are not adequately controlled by steroids and aminosalicylates.
Still, some patients can experience a loss of response to these therapies, particularly anti-TNFs. With Stelara (ustekinumab) being the last biologic approved for Crohn's disease in 2016, there is a demand for therapies with novel MOAs that are less immunogenic than current offerings and many new classes of therapies are looking to enter the industry over the next few years. The biologics such as anti-integrin and interleukin inhibitors are making inroads into the Crohn's Disease market owing to better clinical profile and convenient patient dosing.
Increasing Prevalence of Crohn's Disease: The market studied has been witnessing considerable growth, which can be associated with the increasing prevalence of Crohn's Disease worldwide. As per estimates, the prevalence of Crohn's Disease patients was 18,30,704 in the 8MM in 2020. This number is expected to reach 21,91,344 from 2021 to 2027.
Market Trends:
The Emergence of Microbiome Therapeutics: microbiome-based therapeutics with novel mechanisms are emerging for treating Crohn's Disease. Major players in the industry are developing novel products and spending significantly on research and development, along with major acquisitions and collaborations.
For example, Takeda has entered into a global licensing, co-development, and co-promotion agreement with Enterome S.A. Enterome, BiomX, Synlogics, 4D Pharma, Vedanta Bioscience, and many others are focusing on microbiome-based therapeutics for the treatment of the disease. These players adopt organic and inorganic growth strategies to strengthen their product portfolio.
Market Segmentation
by Drug Class
by Gender Type
by Disease Type
by Age Group
by Geography
Key Vendors
Other Prominent Vendors
Key Milestones
Key Questions Answered:
1. How big is the global Crohn's disease therapeutics market?
2. What is the growth rate of the global Crohn's disease therapeutics market?
3. Who are the key players in the Crohn's disease treatment market?
4. What are the growth factors in the global Crohn's disease therapeutics market?
5. Which country holds the most extensive global Crohn's disease therapeutics market share?
For more information about this report visit https://www.researchandmarkets.com/r/p97qd
View source version on businesswire.com:https://www.businesswire.com/news/home/20221107005654/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 11/07/2022 07:48 AM/DISC: 11/07/2022 07:48 AM
http://www.businesswire.com/news/home/20221107005654/en